Understanding the mechanisms of IL-33 and TSLP production and their modes of action is crucial for the development of therapeutic agents that target the IL-33/ST2 and TSLP/DC pathways, with which to treat ACD and other inflammatory diseases. The gene discussed is IL33; the disease is granular corneal dystrophy type II.